Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797946 | 1.00 | PARP10 (0.50) | PARP10PARP3AKR1C3ALDH1A1MEN1 | |
| SCHEMBL3801854 | 0.89 | AKR1C3 (0.58) | PARP10PARP3AKR1C3ALDH1A1PTGS2 | |
| SCHEMBL13347270 | 0.89 | AKR1C3 (0.58) | PARP10PARP3AKR1C3ALDH1A1PTGS2 | |
| SCHEMBL3801855 | 0.89 | AKR1C3 (0.58) | PARP10PARP3AKR1C3ALDH1A1PTGS2 | |
| SCHEMBL4890342 | 0.85 | ALDH1A1 (0.54) | PARP10PARP3AKR1C3ALDH1A1MEN1 | |
| SCHEMBL4890340 | 0.85 | ALDH1A1 (0.54) | PARP10PARP3AKR1C3ALDH1A1MEN1 | |
| SCHEMBL3797293 | 0.79 | HPGD (0.56) | — | |
| SCHEMBL3797290 | 0.79 | HPGD (0.56) | — | |
| SCHEMBL13347279 | 0.79 | HPGD (0.56) | — | |
| SCHEMBL3797595 | 0.78 | PTGS2 (0.57) | AKR1C3ALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718682-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7407978-B2 | Heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20060235062-A1 | Novel heterocyclic analogs of diphenylethylene compounds | THERACOS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1549625-A1 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | Theracos, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033438-A1 | NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS | THERACOS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | SEED, BRIAN | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181494-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | PARP10 4609/4885PARP3 3864/4885AKR1C3 1902/4885 |
| US-20060235062-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | PARP10 4609/4885PARP3 3864/4885AKR1C3 1902/4885 |
| US-20080293949-A1 | Novel heterocyclic analogs of diphenylethylene compounds | FFAR2, FFAR4, GPR119 | PARP10 4609/4885PARP3 3864/4885AKR1C3 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.